AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 102 min read$AIM

AIM ImmunoTech Inc. (AIM): Results of Operations and Financial Condition

AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0000946644 0000946644 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

Original reporting
SEC EDGAR 8-K
Published Aug 10, 2026, 12:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$AIM
Neutral
low confidence
Mentioned
$AIM
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AIMNeutralLow
01

Why it matters

The filing is a procedural confirmation of results release, but without the Exhibit content, the text provides limited actionable information for valuation or catalyst direction.

02

Market read

Traders should treat this as an earnings disclosure event, but the provided text lacks the figures needed to form a directional view.

03

What to watch

The real trading signal would be in Exhibit 99.1 (the press release), including revenue, margins, cash burn, and any forward-looking statements, none of which are present here.

Relevance 7/10Novelty 3/10Timing: Filed Aug 10, 2026, covering results for quarter ended Jun 30, 2026.

Background

The SEC 8-K indicates AIM issued a press release with financial results for the quarter ended June 30, 2026, attached as Exhibit 99.1.

Company-level read

Ticker impact

$AIMNeutralLow confidence
Context

AIM filed an 8-K for Item 2.02, stating it issued a press release with financial results for the quarter ended June 30, 2026.

Expected impact

Near-term volatility possible on the underlying earnings release, but direction cannot be inferred from the provided text.

Evidence & confidence

The filing confirms results were released, yet the article body contains no numbers, outlook, or qualitative drivers from Exhibit 99.1.

Market effects

Sector

No sector read-through is provided in the scraped text.

Regional

No regional market implications are stated.

Global

No global relevance is stated.

Counterpoint

What could challenge this read

Because the scraped content omits the actual results and any guidance, traders may overreact to the filing itself rather than the earnings details.

Key entities

  • public_company
    AIM ImmunoTech Inc.

    Subject of the SEC Form 8-K, reporting results of operations and financial condition for the quarter ended June 30, 2026.

  • executive
    Thomas K. Equels

    CEO signing the 8-K.

Read at source← All news

Related articles

JUL 23
$AIMMedAI 8/10

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead

AIM ImmunoTech said its Phase 2 pancreatic cancer trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) after FOLFIRINOX reached final patient enrollment ahead of schedule. The company expects to complete dosing and assess the primary Clinical Benefit Rate endpoint in December 2026, while continuing Phase 3 planning and expanding regulatory and IP efforts.

stocktwits.com4 min
JUL 9
$AIMMed

WA gold project Warrawoona fined $118,000 over threatened bat

Australia’s DCCEEW fined AIM Mining Corporation $118,000 for EPBC breaches at its Warrawoona Gold Project in WA’s Pilbara, tied to failure to protect the threatened Pilbara leaf-nosed bat. The regulator cited groundwater extraction over limits, missing species management steps, and reporting failures. AIM said it paid the fine. Calidus previously operated the project.

abc.net.au4 min
JUN 18
$AIMMed

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

AIM ImmunoTech said the final subject has received the first dose in its Phase 2 DURIPANC trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer. Primary endpoint analysis is expected to start in Dec. 2026, with topline results in Q1 2027; secondary endpoint analysis in June 2027. The primary endpoint is clinical benefit rate at 24 weeks.

manilatimes.net3 min
JUN 9
$AIMMedAI 8/10

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

AIM ImmunoTech Inc. (NYSE American: AIM) said it priced a registered direct offering and concurrent private placement under NYSE American rules for gross proceeds of about $2.65 million. The company will issue 2,554,119 registered shares and 2,554,119 unregistered shares (or pre-funded warrants) plus Class J warrants to buy up to 10,216,476 shares at $0.5189. Ladenburg Thalmann is placement agent; closing expected June 10, 2026. Net proceeds will fund clinical drug supply, trials, Phase 3 activi

manilatimes.net4 min